Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies

Xiaoshuang Yuan¹Feiqing Wang^2*Peng Zhao¹Bo Yang²Xu Yang²Ting Tian¹Bingbing Li²Guangyang Liu²Sanbin Wang³Dongxin Tang²Zhixu He⁴Li Yanju¹Yang Liu²

• ¹Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China
• ²The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China
• ³The 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan Province, China
• ⁴Guizhou Medical University, Guiyang, Guizhou Province, China

Background: CD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies.Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and the extent of improvement using CD19 in combination with dual-targeted therapy has not yet been determined. To compare the differences between the two in the treatment of hematological tumors, this study summarized the available evidence. To evaluate and compare the efficacy and safety of CD19-combined CD22 and CD19-combined CD20 CAR T-cell therapy.Methods: Data from 13 clinical studies that included 628 patients with hematological malignancies were extracted and analyzed based on a set of inclusion and exclusion criteria. The primary efficacy outcomes were overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, overall survival (OS) rate and minimal residual disease (MRD)-negative response rate. The safety outcomes were cytokine release syndrome (CRS) rate and immune effector cell-associated neurotoxicity syndrome (ICANS) rate.Results: For CD19 combined with CD22 CAR T-cell therapy, the ORR was 83.7%;